About Lysosome-associated membrane glycoprotein 1
Lysosome-associated membrane glycoprotein 1 (LAMP1) is a protein
from Homo sapiens identified by UniProt accession
P11279, 417 residues long.
MolForge cross-references it against 0 known binders and
435 disease associations.
Target properties
| Protein name | Lysosome-associated membrane glycoprotein 1 |
| UniProt accession | P11279 |
| Gene | LAMP1 |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (435)
Diseases linked to this target (Open Targets).
- high density lipoprotein cholesterol measurement · score 0.24
- neutrophil count · score 0.14
- leukocyte count · score 0.14
- C-reactive protein measurement · score 0.13
- myeloid white cell count · score 0.11
- apolipoprotein A 1 measurement · score 0.10
- infection · score 0.10
- infect · score 0.10
- breast cancer · score 0.08
- cholangiocarcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11279-F1 | alphafold | PREDICTED | 86.43 | — |
Amino-acid sequence (417 residues)
MAAPGSARRP LLLLLLLLLL GLMHCASAAM FMVKNGNGTA CIMANFSAAF SVNYDTKSGP KNMTFDLPSD ATVVLNRSSC GKENTSDPSL VIAFGRGHTL TLNFTRNATR YSVQLMSFVY NLSDTHLFPN ASSKEIKTVE SITDIRADID KKYRCVSGTQ VHMNNVTVTL HDATIQAYLS NSSFSRGETR CEQDRPSPTT APPAPPSPSP SPVPKSPSVD KYNVSGTNGT CLLASMGLQL NLTYERKDNT TVTRLLNINP NKTSASGSCG AHLVTLELHS EGTTVLLFQF GMNASSSRFF LQGIQLNTIL PDARDPAFKA ANGSLRALQA TVGNSYKCNA EEHVRVTKAF SVNIFKVWVQ AFKVEGGQFG SVEECLLDEN SMLIPIAVGG ALAGLVLIVL IAYLVGRKRS HAGYQTI
Explore Lysosome-associated membrane glycoprotein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets